This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Estia Health Future Growth

Future criteria checks 4/6

Estia Health is forecast to grow earnings and revenue by 67% and 7% per annum respectively. EPS is expected to grow by 86.5% per annum. Return on equity is forecast to be 9.5% in 3 years.

Key information

67.0%

Earnings growth rate

86.50%

EPS growth rate

Healthcare earnings growth	20.7%
Revenue growth rate	7.0%
Future return on equity	9.53%
Analyst coverage	Low
Last updated	06 Dec 2023

Recent future growth updates

Recent updates

Estia Health (ASX:EHE) Takes On Some Risk With Its Use Of Debt

Feb 25

Here's Why We Think Estia Health Limited's (ASX:EHE) CEO Compensation Looks Fair

Nov 04

Estia Health (ASX:EHE) Use Of Debt Could Be Considered Risky

Apr 13

Has Estia Health (ASX:EHE) Got What It Takes To Become A Multi-Bagger?

Mar 08

What You Need To Know About Estia Health Limited's (ASX:EHE) Investor Composition

Feb 21

If You Had Bought Estia Health's (ASX:EHE) Shares Five Years Ago You Would Be Down 73%

Jan 24

Did You Manage To Avoid Estia Health's (ASX:EHE) Devastating 75% Share Price Drop?

Jun 17

Earnings and Revenue Growth Forecasts

ASX:EHE - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2026	976	49	N/A	167	3
6/30/2025	941	46	94	149	4
6/30/2024	870	-19	101	172	4
6/30/2023	754	-34	126	187	N/A
3/31/2023	721	-52	75	130	N/A
12/31/2022	689	-70	24	73	N/A
9/30/2022	680	-61	23	64	N/A
6/30/2022	671	-52	22	56	N/A
3/31/2022	668	-25	54	87	N/A
12/31/2021	665	3	86	118	N/A
9/30/2021	656	4	47	86	N/A
6/30/2021	646	6	7	55	N/A
3/31/2021	645	-66	11	66	N/A
12/31/2020	643	-137	14	77	N/A
9/30/2020	640	-127	30	102	N/A
6/30/2020	637	-117	45	126	N/A
3/31/2020	625	-41	27	113	N/A
12/31/2019	612	35	8	101	N/A
9/30/2019	599	38	1	94	N/A
6/30/2019	586	41	-6	88	N/A
3/31/2019	575	42	7	96	N/A
12/31/2018	565	42	20	105	N/A
9/30/2018	556	42	49	121	N/A
6/30/2018	547	41	78	137	N/A
3/31/2018	540	41	85	138	N/A
12/31/2017	533	41	92	139	N/A
9/30/2017	529	41	91	139	N/A
6/30/2017	525	41	90	139	N/A
3/31/2017	517	36	N/A	148	N/A
12/31/2016	510	31	N/A	158	N/A
9/30/2016	476	29	N/A	150	N/A
6/30/2016	443	28	N/A	142	N/A
3/31/2016	400	27	N/A	146	N/A
12/31/2015	357	27	N/A	150	N/A
9/30/2015	321	2	N/A	127	N/A
6/30/2015	285	-23	N/A	104	N/A
3/31/2015	228	-30	N/A	71	N/A
12/31/2014	171	-38	N/A	38	N/A
9/30/2014	119	-26	N/A	24	N/A
6/30/2014	67	-14	N/A	10	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EHE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).

Earnings vs Market: EHE is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EHE is expected to become profitable in the next 3 years.

Revenue vs Market: EHE's revenue (7% per year) is forecast to grow faster than the Australian market (5.2% per year).

High Growth Revenue: EHE's revenue (7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: EHE's Return on Equity is forecast to be low in 3 years time (9.5%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/12/19 12:53
End of Day Share Price	2023/12/06 00:00
Earnings	2023/06/30
Annual Earnings	2023/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Estia Health Limited is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Russell Wright	APP Securities Pty Ltd.
Russell Wright	Barclay Pearce Capital Pty Limited
William Dunlop	BofA Global Research

This company listing is no longer active

Estia Health Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 30%, revenue upgraded

Consensus EPS estimates fall by 16%

Consensus EPS estimates fall by 15%

Price target increased by 12% to AU$2.83

Consensus EPS estimates fall by 22%, revenue upgraded

Consensus forecasts updated

Recent updates

Estia Health Limited Announces Cessation of Helen Kurincic as Director

Consensus EPS estimates fall by 30%, revenue upgraded

New minor risk - Dividend sustainability

Estia Health Limited Announces Dividend, Payable on September 15, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 16%

Estia Health Limited (ASX:EHE) entered into a binding agreement to acquire residential aged care homes in Benalla of Royal Freemasons Ltd.

Estia Health Limited to Report Fiscal Year 2023 Results on Aug 22, 2023

Bain Capital Reportedly Moves to Sell Craigcare But Abandons Its Pursuit of Estia

Consensus EPS estimates fall by 15%

Price target increased by 12% to AU$2.83

Independent Non-Executive Chairman recently bought AU$52k worth of stock

Consensus EPS estimates fall by 22%, revenue upgraded

First half 2023 earnings released: AU$0.098 loss per share (vs AU$0.031 loss in 1H 2022)

Estia Health Limited to Report First Half, 2023 Results on Feb 21, 2023

CEO, MD & Director recently bought AU$106k worth of stock

Consensus forecasts updated

Estia Health Limited Announces Retirement of Mr. Steve Lemlin, Chief Financial Officer

Consensus estimates of losses per share improve by 51%

Estia Health Limited, Annual General Meeting, Nov 03, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Estia Health Limited Announces Appointment of Simon Willcock as Non-Executive Director Effective 1 September 2022

Estia Health Limited Appoints Sean Bilton as Director

Estia Health Limited to Report Fiscal Year 2022 Results on Aug 23, 2022

Consensus forecasts updated

Insufficient new directors

Estia Health Limited Announces Management Changes

Estia Health Limited announces resignation of Hon. Warwick L. Smith AO as director, effective 31 March 2022

Consensus forecasts updated

Estia Health (ASX:EHE) Takes On Some Risk With Its Use Of Debt

First half 2022 earnings: EPS misses analyst expectations

Estia Health Limited Announces Dividend for the Six Months Ended December 31, 2021, Payable on March 18, 2022

Consensus forecasts updated

Here's Why We Think Estia Health Limited's (ASX:EHE) CEO Compensation Looks Fair

Insufficient new directors

Full year 2021 earnings released: EPS AU$0.023 (vs AU$0.45 loss in FY 2020)

Estia Health (ASX:EHE) Use Of Debt Could Be Considered Risky

Price target increased to AU$2.15

Has Estia Health (ASX:EHE) Got What It Takes To Become A Multi-Bagger?

Price target raised to AU$1.94

First half 2021 earnings released: AU$0.02 loss per share (vs AU$0.055 profit in 1H 2020)

Estia Health Limited Not Declare Interim Dividend for the Six Months Ended December 31, 2020

What You Need To Know About Estia Health Limited's (ASX:EHE) Investor Composition

Estia Health Limited Reaches an Agreement to Settle the Shareholder Class Action Commenced Against It in July 2019

New 90-day high: AU$1.96

If You Had Bought Estia Health's (ASX:EHE) Shares Five Years Ago You Would Be Down 73%

Is Estia Health (ASX:EHE) Using Too Much Debt?

Estia Health Limited to Report Q2, 2021 Results on Feb 23, 2021

Have Insiders Been Buying Estia Health Limited (ASX:EHE) Shares?

New 90-day high: AU$1.63

New 90-day low: AU$1.36

New 90-day low: AU$1.37

Estia Health Limited Determines Not to Declare A Final Dividend for Fiscal Year 2020

Did Estia Health Limited (ASX:EHE) Insiders Buy Up More Shares?

Is There Now An Opportunity In Estia Health Limited (ASX:EHE)?

Estia Health Limited(ASX:EHE) dropped from S&P/ASX 200 Index

Did You Manage To Avoid Estia Health's (ASX:EHE) Devastating 75% Share Price Drop?

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources